Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Achilles Therapeutics

13.05.2020

Achilles Therapeutics announces formation of Scientific Advisory Board

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumor target, today announced the formation of a Scientific Advisory Board (SAB) with three world-renowned appointments: Dr Elizabeth M. Jaffee, Dr Scott Antonia and Dr Christopher A. Klebanoff. The SAB will work closely with Achilles’ senior management team and Founders to advance the Company’s pipeline of solid tumor cancer therapies.
Achilles Therapeutics

22.04.2020

Achilles Therapeutics to present a manufacturing update at the virtual 2020 AACR Annual Meeting

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced that it will present a manufacturing update using the VELOSTM manufacturing platform for its lead programs at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting.
Achilles Therapeutics

07.04.2020

Achilles Therapeutics appoints Carsten Boess to the Board of Directors

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the appointment of Carsten Boess as Non-Executive Director to its Board, effective 1 April 2020.
Achilles Therapeutics

17.03.2020

Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer

Achilles Therapeutics (“Achilles”), a clinical stage oncology company developing personalised cell therapies targeting clonal neoantigens (a novel class of tumour target), today announced the appointment of Professor Sergio Quezada as Chief Scientific Officer (CSO) with effect from 6 April 2020.
Achilles Therapeutics

07.01.2020

Achilles Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Achilles Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Achilles Therapeutics

21.10.2019

Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer

Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces it has appointed Beverley Carr as Chief Business Officer, with effect from 4 November 2019.
Achilles Therapeutics

13.02.2019

Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma

Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of its Clinical Trial Application (CTA) to conduct a Phase I/II study using clonal neoantigen targeting T cells (cNeT) in patients with metastatic or recurrent melanoma. The study is expected to enrol the first patient later in 2019.
Achilles Therapeutics

12.02.2019

Achilles Therapeutics appoints Dr Markus Dangl as Chief Scientific Officer

Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the appointment of Dr Markus Dangl as Chief Scientific Officer (CSO).
Achilles Therapeutics

21.01.2019

Achilles Therapeutics receives CTA approval for Phase I/II Study in Non-Small Cell Lung Cancer

Achilles Therapeutics (“Achilles””), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical Trial Application (CTA) to conduct a Phase I/II study with its lead product, a tumour-derived T cell therapy targeting clonal neoantigens, in development for the treatment of advanced Non-Small Cell Lung Cancer (NSCLC), has been approved by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA). The study, an open-label, multi-centre Phase I/II trial evaluating the safety and clinical activity of clonal neoantigen T cells (cNeT) in patients with advanced NSCLC, is expected to enrol the first patient in 2H 2019.
Achilles Therapeutics

10.12.2018

Achilles Therapeutics Appoints Dr Edwin Moses as Chairman of its Board of Directors and Dr Iraj Ali as Chief Executive Officer

Stevenage, UK 10 December 2018 – Achilles Therapeutics (“Achilles” or “the Company”), a biopharmaceutical company using neoantigens to develop personalised cancer immunotherapies, today announces that it has appointed Dr Edwin Moses as Chairman of its Board of Directors. In addition, Dr Iraj Ali, currently Interim CEO, will become the permanent, full-time CEO of the Company.

Load More